Danuglipron

Bengaluru: Pfizer said on Tuesday it would generate $1.7 billion more in savings from cost cuts to its manufacturing and research operations, highlighting its operational efficiency even as it reported lower first-quarter revenue due to declining sales of its COVID-19 treatment Paxlovid. Chief Executive Albert Bourla, speaking on a conference call with investors, said the drugmaker's story over the next three years would not be one of strong revenue growth, given looming patent expirations on top products, but rather one of earnings growth. The company reaffirmed its full-year forecast, and shares were up nearly 4 per cent. Pfizer also said it had measures in place to mitigate the impact of potential tariffs on pharmaceuticals by the Trump administration, including possibly shifting some production to existing facilities in the United States. "We have huge manufacturing capacity right now in the U.S., particularly for everything that is injectable," Bourla said. "If there is a need, it's clearly there, and without the need to build new facilities." Pfizer has 10 manufacturing sites and two distribution centers in the United States, employing nearly 10,000 people. While the rates and timing of tariffs on the pharma sector are unclear, analysts expect that companies will have to absorb any near-term costs if they are imposed. Washington has launched an investigation into the industry, laying the groundwork for possible levies. Bourla in an interview said the industry is hoping the Trump administration will focus more on medicines like those the World Health Organization has designated as essential, which tend to be off-patent and produced mostly in China and India. "I think that's where the problem is. It's not if an obesity drug is made in Ireland," he said. LEANING ON COST SAVINGS The company said it now expects about $7.7 billion in savings by the end of 2027 from its cost-cutting programs. That includes an additional $500 million in R&D savings, which at least two investors said could reflect Pfizer's recent decision to stop development of its experimental weight-loss pill danuglipron. "The cost savings are real, it does help drive better bottom line performance," said Brian Mulberry, portfolio manager at Zacks Investment Management, which owned 2.44 million Pfizer shares at the end of 2024. "We just want to know where that top-line growth is going to come from." Not from COVID antiviral Paxlovid, apparently. Sales of the two-drug treatment were $491 million, well short of analysts' already diminished expectations of $794.3 million, according to LSEG data. Analysts significantly cut their Paxlovid sales expectations in recent weeks due to a relatively small winter wave of COVID-19 in the U.S. On an adjusted basis, Pfizer earned 92 cents per share in the first quarter, topping analysts' expectations by 26 cents, helped by cost cuts and a lower tax rate. Despite the earnings beat, Pfizer is still forecasting a full-year adjusted profit of $2.80 to $3.00 per share on revenue of $61 billion to $64 billion. CFO David Denton said Pfizer was "currently trending toward the upper end" of its profit forecast. Revenue in the quarter fell 8 per cent from a year ago to $13.72 billion and missed analysts' expectations of $13.91 billion. Potential tariffs could add to existing pressure for Pfizer. Investors have been pushing the company to bring new drugs to market that could make up for revenue likely to be lost from some top-selling medicines nearing the end of patent protection. Zacks' Mulberry said the company has done well at becoming more productive on the manufacturing side. "That's where they're finding a bulk of the savings at this point," he said, "but I don't see the next kind of really big pop in revenue." Even the drugs that outperformed Wall Street expectations in the first quarter face headwinds. Sales of its heart disease drug, sold under the brand names Vyndaqel and Vyndamax, were $1.49 billion, above estimates of $1.29 billion. But the company said it is already seeing the impact of new competition, which it expects to continue through the year. Pfizer's vaccine business could also face greater regulatory scrutiny under the new Health Secretary Robert F. Kennedy Jr., a longtime vaccine skeptic. COVID vaccine Comirnaty, which Pfizer makes with German partner BioNTech, brought in sales of $565 million. Analysts were expecting $331.7 million for the shot in the first quarter. (Reporting by Bhanvi Satija and Christy Santhosh in Bengaluru and Michael Erman in New York; Editing by Anil D'Silva and Bill Berkrot)

1. 95岁屠呦呦，当选美国科学院院士屠呦呦当选美国科学院外籍院士，她是青蒿素研究中心主任，多年从事中药研究，曾获诺贝尔奖等多项荣誉。2. 浙江大学新突破：中药益生菌联手，攻克脂肪肝难题，代谢焕新浙江大学最新研究发现，中药与益生菌联合使用（TCMP）能够有效缓解高脂饮食（HFD）引起的肥胖和脂肪肝问题。该研究通过小鼠实验表明，TCMP显著降低了HFD喂养小鼠的体重和脂肪积累，改善了代谢状况。相比于单独使用中药或益生菌，TCMP在调节肠道微生物群、增强肠道屏障功能以及提升免疫系统方面表现出更显著的效果。这项突破性成果为治疗由高脂饮食引发的慢性疾病提供了新的方向，并展示了中医药与现代益生菌结合的巨大潜力。3. 女性“高潮针”大火，医生：系商家创造概念，无医学依据女性“高潮针”引发争议，医生指出这是商家创造的概念，无医学依据，涉及填充剂、PRP和干细胞等技术，但干细胞治疗仍处于试验阶段。同时，全国10省份实现生育津贴直发到个人，首批长期照护师证书在江苏颁发，标志着照护服务迈向职业化。4. 减肥药“断腕”、核心药物承压，辉瑞欲“买买买”加码心脏代谢短板辉瑞在2025年第一季度财报中披露，由于口服减肥药Danuglipron研发受挫，公司将通过收购或合作加速布局心脏代谢领域，以弥补产品线空缺。尽管Q1营收未达预期，但调整后每股收益超预期，公司维持全年盈利指引上限。新冠产品表现不一，Paxlovid收入低于预期，而Comirnaty疫苗超出预期。核心药物如Eliquis销售额下滑。为应对业绩波动，辉瑞升级成本管控计划，预计到2027年底累计节省57亿美元。辉瑞CEO表示将通过内部研发和外部合作构建心脏代谢领域产品矩阵。分析师认为，通过收购或合作快速补充产品线是突破增长瓶颈的关键。5. 最高支持1.5亿，天津“生物制造十条”发布，12大项目签约天津港保税区发布生物制造行动方案和政策，旨在打造百亿级产业集群，提出阶段性目标，并通过具体支持举措促进生物制造产业发展。6. 海口国家高新区：打造千亿级生物医药产业集群海口国家高新区致力打造千亿级生物医药产业群，通过强化平台支撑、深化区域协同和优化服务配套三个层面推进高质量发展，已成为海南生物医药核心承载区。本文仅用于学术分享，转载请注明出处。若有侵权，请联系微信：bioonSir 删除或修改！